Department of Internal Medicine, Hematology and Oncology, Goethe University Frankfurt, Frankfurt, Germany.
4th Department of Internal Medicine, Klinikum Leverkusen gGmbH, Leverkusen, Germany.
Infection. 2021 Aug;49(4):725-737. doi: 10.1007/s15010-021-01597-7. Epub 2021 Apr 13.
The ongoing pandemic caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2) has stressed health systems worldwide. Patients with chronic kidney disease (CKD) seem to be more prone to a severe course of coronavirus disease (COVID-19) due to comorbidities and an altered immune system. The study's aim was to identify factors predicting mortality among SARS-CoV-2-infected patients with CKD.
We analyzed 2817 SARS-CoV-2-infected patients enrolled in the Lean European Open Survey on SARS-CoV-2-infected patients and identified 426 patients with pre-existing CKD. Group comparisons were performed via Chi-squared test. Using univariate and multivariable logistic regression, predictive factors for mortality were identified.
Comparative analyses to patients without CKD revealed a higher mortality (140/426, 32.9% versus 354/2391, 14.8%). Higher age could be confirmed as a demographic predictor for mortality in CKD patients (> 85 years compared to 15-65 years, adjusted odds ratio (aOR) 6.49, 95% CI 1.27-33.20, p = 0.025). We further identified markedly elevated lactate dehydrogenase (> 2 × upper limit of normal, aOR 23.21, 95% CI 3.66-147.11, p < 0.001), thrombocytopenia (< 120,000/µl, aOR 11.66, 95% CI 2.49-54.70, p = 0.002), anemia (Hb < 10 g/dl, aOR 3.21, 95% CI 1.17-8.82, p = 0.024), and C-reactive protein (≥ 30 mg/l, aOR 3.44, 95% CI 1.13-10.45, p = 0.029) as predictors, while renal replacement therapy was not related to mortality (aOR 1.15, 95% CI 0.68-1.93, p = 0.611).
The identified predictors include routinely measured and universally available parameters. Their assessment might facilitate risk stratification in this highly vulnerable cohort as early as at initial medical evaluation for SARS-CoV-2.
由新型严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的持续大流行使世界各地的卫生系统承受了巨大压力。患有慢性肾脏病(CKD)的患者由于合并症和免疫系统改变,似乎更容易出现冠状病毒病(COVID-19)的严重病程。本研究旨在确定预测 SARS-CoV-2 感染合并 CKD 患者死亡率的因素。
我们分析了纳入 Lean European Open Survey on SARS-CoV-2-infected patients 的 2817 例 SARS-CoV-2 感染患者,其中识别出 426 例存在预先存在的 CKD 的患者。通过卡方检验进行组间比较。使用单变量和多变量逻辑回归,确定死亡率的预测因素。
与无 CKD 的患者相比,CKD 患者的死亡率更高(140/426,32.9%比 354/2391,14.8%)。较高的年龄可被确认为 CKD 患者死亡率的人口统计学预测因素(>85 岁比 15-65 岁,调整后的优势比(aOR)6.49,95%CI 1.27-33.20,p=0.025)。我们进一步发现乳酸脱氢酶显著升高(>2×正常值上限,aOR 23.21,95%CI 3.66-147.11,p<0.001)、血小板减少症(<120,000/µl,aOR 11.66,95%CI 2.49-54.70,p=0.002)、贫血(Hb<10 g/dl,aOR 3.21,95%CI 1.17-8.82,p=0.024)和 C 反应蛋白(≥30 mg/l,aOR 3.44,95%CI 1.13-10.45,p=0.029)是预测因素,而肾脏替代治疗与死亡率无关(aOR 1.15,95%CI 0.68-1.93,p=0.611)。
所确定的预测因素包括常规测量和普遍可用的参数。在对 SARS-CoV-2 进行初始医学评估时,对这些高危人群进行评估可能有助于进行风险分层。